Bone-selective osteogenic oxysterol-bone targeting agents
US-2016159850-A1 · Jun 9, 2016 · US
US10214557B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10214557-B2 |
| Application number | US-201715600375-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 19, 2017 |
| Priority date | Dec 9, 2014 |
| Publication date | Feb 26, 2019 |
| Grant date | Feb 26, 2019 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Compounds and methods of synthesizing oxysterols are provided. The compounds and methods provided allow the oxysterol to be safely produced at a high yield. The compounds and methods provided can produce the oxysterol in a stereoselective manner. The oxysterols of the current application can be used in effective amounts to grow bone.
Opening claim text (preview).
What is claimed is: 1. A method of making an oxysterol, the method comprising reacting a diol having the formula: with a borane compound to form the oxysterol or a pharmaceutically acceptable salt or solvate thereof having the formula: wherein R1 is a straight chain alkyl, and R2 is a straight chain alkyl, and the oxysterol is anhydrous. 2. The method of claim 1 , wherein the borane compound is BH 3 and is reacted with a peroxide. 3. The method of claim 2 , wherein the peroxide is hydrogen peroxide. 4. The method of claim 3 , wherein the BH 3 and the hydrogen peroxide are reacted in the presence of tetrahydrofuran to form the oxysterol. 5. The method of claim 4 , wherein (i) the borane is reacted with the diol at a temperature of less than 5° C., (ii) the hydrogen peroxide is reacted with the diol at a temperature of less than 15° C., or (iii) the oxysterol is solidified and separated by filtration. 6. The method of claim 1 , wherein the reaction is carried out in a single container to yield the oxysterol having the formula or a pharmaceutically acceptable salt or solvate thereof. 7. The method of claim 1 , wherein the oxysterol is purified by dissolving the oxysterol in an organic solvent. 8. The method of claim 1 , wherein the borane compound is reacted with the diol at a temperature of less than 5° C. 9. The method of claim 4 , wherein the hydrogen peroxide is reacted with the diol after the borane is reacted and the hydrogen peroxide is reacted with the diol at a temperature of less than 15° C. 10. The method of claim 1 , wherein the reaction is carried out in a single container to yield the oxysterol. 11. A method of making an oxysterol, the method comprising reacting a diol having the formula: with borane, hydrogen peroxide and tetrahydrofuran to form the oxysterol or a pharmaceutically acceptable salt or solvate thereof having the formula: wherein R1 is a straight chain alkyl and R2 is a straight chain alkyl, and the oxysterol is anhydrous. 12. The method of claim 11 , wherein (i) the diol is (3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(S)-2-hydroxyoctan-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol or (ii) the oxysterol is 3S,5S,6S,8R,9S,10R,13S,14S,17S)-17-((S)-2-hydroxyoctan-2-yl)-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthrene-3,6-diol. 13. The method of claim 11 wherein the reaction is carried out in a single container to yield the oxysterol having the formula: or a pharmaceutically acceptable salt or solvate thereof.
Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane · CPC title
not substituted in position 16 · CPC title
Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton (cardanolide, bufanolide C07J19/00) · CPC title
Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00 · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.